| 1. |
- Hull, Christopher M., et al.
(author)
-
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions : A randomized, double-blind, placebo-controlled, patient-initiated clinical trial
- 2011
-
In: The Journal of American Academy of Dermatology. - : Elsevier BV. - 0190-9622 .- 1097-6787. ; 64:4, s. 696-705
-
Journal article (peer-reviewed)abstract
- Background: Prior pilot studies support the use of antiviral medications with topical corticosteroids for herpes simplex labialis (HSL). ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL. Objectives: The primary study end point was the prevention of ulcerative HSL lesions. Methods: In all, 2437 patients with a history of HSL were randomized to self-initiate treatment with ME-609, 5% acyclovir in ME-609 vehicle, or ME-609 vehicle (placebo) at the earliest sign of a cold sore recurrence. Cream was applied 5 times/d for 5 days. A total of 1443 patients experienced a recurrence and initiated treatment with ME-609 (n = 601), acyclovir (n = 610), or placebo (n = 232). Results: Of patients receiving ME-609, 42% did not develop an ulcerative lesion compared with 35% of patients receiving acyclovir in ME-609 vehicle (P = .014) and 26% of patients receiving placebo (P < .0001). In patients with ulcerative lesions, healing times were reduced in the ME-609 and acyclovir groups compared with placebo (P < .01 for both). The cumulative lesion area for all lesions was reduced 50% in patients receiving ME-609 compared with the placebo group (P < .0001). There were no differences among groups in the number of patients with positive herpes simplex virus cultures. The side-effect profile was similar among treatments. Limitations: The study did not contain a group treated with a topical corticosteroid alone. Conclusions: ME-609 prevented progression of cold sores to ulcerative lesions and significantly reduced the cumulative lesion area compared with acyclovir and placebo. ME-609 treatment offers additional therapeutic benefit compared with therapy with topical acyclovir alone. (J Am Acad Dermatol 2011;64:696-705.)
|
|
| 2. |
|
|
| 3. |
- Mård Karlsson, Johanna, 1979-, et al.
(author)
-
Opportunities and limitations to detect climate-related regime shifts in inland Arctic ecosystems through eco-hydrological monitoring
- 2011
-
In: Environmental Research Letters. - : IOP Publishing. - 1748-9326. ; 6:1, s. 014015-
-
Journal article (peer-reviewed)abstract
- This study has identified and mapped the occurrences of three different types of climate-driven and hydrologically mediated regime shifts in inland Arctic ecosystems: (i) from tundra to shrubland or forest, (ii) from terrestrial ecosystems to thermokarst lakes and wetlands, and (iii) from thermokarst lakes and wetlands to terrestrial ecosystems. The area coverage of these shifts is compared to that of hydrological and hydrochemical monitoring relevant to their possible detection. Hotspot areas are identified within the Yukon, Mackenzie, Barents/Norwegian Sea and Ob river basins, where systematic water monitoring overlaps with ecological monitoring and observed ecosystem regime shift occurrences, providing opportunities for linked eco-hydrological investigations that can improve our regime shift understanding, and detection and prediction capabilities. Overall, most of the total areal extent of shifts from tundra to shrubland and from terrestrial to aquatic regimes is in hydrologically and hydrochemically unmonitored areas. For shifts from aquatic to terrestrial regimes, related water and waterborne nitrogen and phosphorus fluxes are relatively well monitored, while waterborne carbon fluxes are unmonitored. There is a further large spatial mismatch between the coverage of hydrological and that of ecological monitoring, implying a need for more coordinated monitoring efforts to detect the waterborne mediation and propagation of changes and impacts associated with Arctic ecological regime shifts.
|
|
